Search Results
Your search for The ASCO ,The ASCO matches 21410 pages
Showing 15401 - 15450QOPI-Certified Practices Eligible to Receive Discount on Medical Malpractice Rates
ASCO and its wholly owned subsidiary, Quality Oncology Practice Initiative (QOPI®) Certification Program, LLC (QCP), announced May 25 that The Doctors Company, the nation's largest physician-owned medical malpractice insurer, will recognize QOPI® Certification in its rate structure....
DDW 2016: Rates of Colorectal Cancer Continue to Increase in Those Under 50
A new study shows the rate of colorectal cancer continues to increase in individuals under 50 years old, despite the fact that the overall rate of the disease has been declining in recent years. Following examination of more than 1 million colorectal cancer patient records over 10 years,...
DDW 2016: Low-Residue Diet Prior to Colonoscopy Shows Improved Tolerance and Bowel Preparation vs Clear Liquid Diet
A new study finds that patients who ate certain solid foods, considered “low residue,” were better prepared for their colonoscopies than individuals who followed the conventional liquid diet. Additionally, researchers saw that these patients who ate foods such as eggs, white bread,...
DDW 2016: Racial Disparities Found in Liver Cancer Survival Rates
Black patients diagnosed with hepatocellular carcinoma, the most common liver cancer, had a 33% increased risk of death compared to non-Hispanic whites. They also were far less likely to receive lifesaving liver transplants, according to a new study presented by Jones et al at Digestive Disease...
DDW 2016: Endoscopist’s Knowledge of Positive Cologuard Test Improves Colonoscopy Performance
An endoscopist's knowledge of a positive Cologuard test improves colonoscopy performance, according to a poster presentation by Johnson et al at Digestive Disease Week (DDW) 2016 (Abstract Su1044). Cologuard is an at-home, stool-DNA colorectal cancer screening test that has been approved by the...
New ASCO Cervical Cancer Guidelines Address Global Resource Disparities
On May 25, ASCO issued its first clinical practice guideline on invasive cervical cancer. This resource-stratified guideline is the first of its kind from ASCO, offering treatment recommendations tailored to resource availability. Access to cervical cancer care varies between regions of the...
External Validation of a Prediction Tool for Chemotherapy Toxicity in Older Patients With Cancer
Hurria et al validated a prediction tool for chemotherapy toxicity in cancer patients aged ≥ 65 years in an external cohort, according to a report in the Journal of Clinical Oncology. The predictive model had been developed in a prior study in 500 patients. Study Details The study...
Play-Based Procedural Preparation May Aid Children Undergoing Cranial Radiation Therapy
Play-based procedural preparation not only helps children cope with the stress and anxiety of radiation therapy, but can also help reduce the amount of sedation used and cut costs, according to a study from the Child Life Program at St. Jude Children’s Research Hospital. The study was...
Colleagues Tip Their Hats to Allen S. Lichter, MD, FASCO
After serving as ASCO’s CEO for 10 years, Allen S. Lichter, MD, FASCO, is stepping down. Dr. Lichter, who has been an ASCO member since 1980, has served the Society in numerous capacities. Along with his distinguished career at ASCO, Dr. Lichter is a nationally recognized radiation oncologist,...
2016 Oncology Meetings
MAY Lymphoma: State-of-the-Art in Biology Therapy, and Patient CareMay 13-14 • New York, New YorkFor more information: msklymphoma2016.com NCI “Sandpit” on Individual and Contextual Factors of Population-Level Cancer ControlMay 16-18 • Montgomery County, MarylandFor more...
Surgical Oncologist Suzanne L. Topalian, MD, Shines at the Forefront of Groundbreaking Research in Cancer Immunotherapy
Nationally recognized surgical oncologist and researcher Suzanne L. Topalian, MD, had an early interest in the arts as well as science and decided to major in English upon entering Wellesley College in Wellesley, Massachusetts. “I wanted to keep all my options open, so I also enrolled in a pre-med...
Noted Gastrointestinal Oncologist Leonard Saltz, MD, Tempers Optimism With Reality and Factors Cost Into the Equation of Value in Cancer Care
Leonard Saltz, MD, was born in New York, New York, and reared in Westchester County, in the suburbs of the City. Terrance Archer, his high-school biology teacher, whom Dr. Saltz described as a “force of nature,” a wonderful human being, and a major role model, influenced his nascent curiosity in...
In Memoriam
The ASCO Post remembers the following specialists in oncology who passed away in 2015–2016. Please write to editor@ASCOPost.com to recognize and pay tribute to others in a future issue. Mark R. Green, MD January 3, 1945–February 23, 2015 “Few people have impacted cancer clinical research in the...
Recipients of the David A. Karnofsky Memorial Award and Lecture
David A. Karnofsky, MD, dedicated himself to the pursuit of scientific excellence and the investigation of more effective therapies for cancer for nearly 30 years, from the time he was a resident at the Collis P. Huntington Memorial Hospital for Cancer Research of Harvard University, until his...
Physician-Researcher Carolyn Jean Presley, MD, Envisions Enhancing Geriatric Oncology
Carolyn Jean Presley, MD, a Robert Wood Johnson Foundation clinical scholar in medical oncology at the Yale Cancer Center, was born in Duluth, Minnesota, which hugs the north shore of Lake Superior, making it one of the nation’s coldest cities during its long winters. She grew up the middle child...
Lisa A. Newman, MD, MPH, FACS, FASCO, Balances Her Passions of Surgical Breast Oncology and Breast Cancer Disparity Research, Both Home and Abroad
Lisa A. Newman, MD, MPH, FACS, FASCO, Director of the Henry Ford Health System’s Breast Oncology Program, was born in New York, New York and, according to her, was blessed to have had parents who lived the African American version of the “American Dream.” Dr. Newman’s father was the son of...
With a Strong Personal Connection to His Patients, Stephen P. Hunger, MD, Strives for a Cure for All Children With Leukemia
Nationally regarded children’s cancer specialist Stephen P. Hunger, MD, was born and reared in South Windsor, a small suburb of Hartford, Connecticut. Dr. Hunger grew up in the mid-1960s and 1970s, and in his words, “South Windsor was a pretty homogeneous experience. There wasn’t really any ethnic...
International Authority on Radiation Effects, Robert Peter Gale, MD, PhD, Has Pushed Scientific Boundaries in Search of Answers
It is widely reported that the first use of sargramostim (Leukine) in humans (granulocyte macrophage colony-stimulating factor; GM-CSF) was to treat victims of the Goiânia, Brazil, radiation accident in 1987. However, recently declassified documents show that sargramostim was first used a year...
About the Contributors
Ronald Piana is an independent writer and reporter with more than 20 years of experience in oncology communications and publishing. In addition to the profiles published in this special supplemental issue of The ASCO Post, Ron has written more than 100 news and feature articles, interviews, and...
Once a Vocational Nomad, Christine H. Chung, MD, Now Works to Promote Patient-Centered Care in Head and Neck Cancer
Christine H. Chung, MD, Chair of the Department of Head and Neck-Endocrine Oncology at Moffitt Cancer Center, Tampa, Florida, was born and reared in Seoul, Republic of Korea. Dr. Chung immigrated with her mother and two brothers to Los Angeles, where her family then resided. Dr. Chung did not speak ...
Celebrating ASCO 2016 Awards Recipients
Peter Paul Yu, MD, FACP, FASCO, Immediate Past President of ASCO and Chair of the Special Awards Selection Committee, announced the recipients of this year’s special awards. “The exceptional accomplishments of each of our awardees reflect their exemplary dedication to furthering cancer research and ...
With an Illustrious Career in Breast Oncology, Daniel F. Hayes, MD, FASCO, Follows in the Footsteps of Giants as ASCO President-Elect
ASCO President-Elect Daniel F. Hayes, MD, FASCO, was born in Shelbyville, Indiana, a small city in the center of the state. “My dream was to become a high school basketball and track and field coach; my older brother wanted to be a doctor, and his ambitions also began in first grade,” revealed Dr....
Allen S. Lichter, MD, FASCO, Reflects on His Career Path and His Tenure as ASCO CEO, and Predicts a Bright Future for Radiation Oncology
Choosing a career path is one of life’s most challenging decisions, but for Allen S. Lichter, MD, FASCO, deciding to become a doctor was inherently natural. He was born with a great mentor and role model: his father. “I was born and raised in Detroit. My father was a general practitioner in...
Monitoring Survivors of Childhood Cancers for Late Effects of Treatment
This past January, ASCO held its inaugural Cancer Survivorship Symposium, which brought together the fields of medical oncology and primary care to address the critical need for coordinated care for cancer survivors. Among the presenters at the symposium was Smita Bhatia, MD, MPH, who gave the...
Occupational Therapy for Adults With Cancer: An Unmet Need
Adults with cancer are at high risk for functional limitations that would negatively affect their quality of life. Occupational therapy offers a range of supportive services, with the specific goal of helping these patients engage in life as independently as possible. To provide a better...
A Toolkit for Dealing With the Trauma of a Prostate Cancer Diagnosis
This year, an estimated 180,890 men in the United States will be diagnosed with prostate cancer; about 21,120 men die of the disease each year. On top of these sobering statistics, from screening to diagnosis and treatment, prostate cancer is fraught with controversy, creating untoward anxiety...
A Physician’s Guide to Pain and Symptom Management in Cancer Patients
Despite growing awareness and the existence of guidelines, undertreatment of cancer pain remains a persistent dilemma in the oncology community. Researchers from The University of Texas MD Anderson Cancer Center found that more than 33% of patients suffering from invasive cancer do not receive...
Leading Surgical Oncology Societies Call for Global Curriculum to Address Variations, Inadequacies in Training
The lack of an adequately trained workforce of surgical oncologists can be a major detriment in efforts to address the rising global cancer burden, according to two leading international surgical oncology societies. In two jointly published reports,1,2 the Society of Surgical Oncology (SSO) and the ...
ASCO’s State Affiliate Council Improves Communication Between ASCO and Community Physicians
ASCO established a State Affiliate Council in 2012 consisting of representatives from each of the Society’s 48 state or regional oncology societies. The Council met on April 21–22 at ASCO headquarters in Alexandria, Virginia. The ASCO Post talked with Paul Celano, MD, FACP, President, Maryland/DC...
AUA, SUO Release New Clinical Practice Guideline on the Diagnosis and Treatment of Non–Muscle-Invasive Bladder Cancer
The American Urological Association (AUA), together with the Society for Urologic Oncology (SUO), has released a new clinical practice guideline on non–muscle-invasive bladder cancer. This new document outlines guidance on a variety of topics, including diagnosis and treatment, as well as a...
$200 Million Gift Launches Lawrence J. Ellison Institute for Transformative Medicine of USC
Technology entrepreneur Larry Ellison has donated $200 million to establish the Lawrence J. Ellison Institute for Transformative Medicine of the University of Southern California (USC), a new center in Los Angeles that will combine interdisciplinary research with the holistic prevention and...
ASCO Past-President Anticipates a New Position With an Ongoing Goal of Advancing the Field of Oncology
After an extensive national search, Hartford HealthCare has appointed ASCO Past-President Peter Paul Yu, MD, FACP, FASCO, as the first Physician-in-Chief of the Hartford HealthCare Cancer Institute. As Physician-in-Chief, Dr. Yu will be responsible for working closely and collaboratively with...
Robert S. Langer, ScD, Receives 2016 AACR-Irving Weinstein Foundation Distinguished Lectureship
The American Association for Cancer Research (AACR) honored Robert S. Langer, ScD, with the 2016 AACR-Irving Weinstein Foundation Distinguished Lectureship at the AACR Annual Meeting 2016, held in New Orleans, on April 16–20. The AACR-Irving Weinstein Foundation Distinguished Lectureship was...
Brian Czerniecki, MD, PhD, Named Chair of Breast Oncology at Moffitt
Moffitt Cancer Center has announced that Brian Czerniecki, MD, PhD, has joined the faculty and will serve as the Chair and a member of the Department of Breast Oncology. Dr. Czerniecki is recognized for his contribution to the development of sentinel lymph node mapping. He joins Moffitt after...
NIH Appoints Patricia Flatley Brennan, RN, PhD, to Lead the NLM
National Institutes of Health (NIH) Director Francis S. Collins, MD, PhD, has named Patricia Flatley Brennan, RN, PhD, Director of the National Library of Medicine (NLM). The NLM is the world’s largest biomedical library and the producer of digital information services used by scientists,...
Eribulin in Liposarcoma: A Closer Look at the Comparative Data
Sarcoma therapy is a challenge for oncologists. Soft-tissue sarcomas encompass more than 50 different histologies, resulting in limited familiarity of management for many treating physicians. In addition, there have been few available effective therapies. The phase III trial of eribulin (Halavan) ...
Increased Physical Activity Associated With Lower Risk of 13 Types of Cancer
A new study of the relationship between physical activity and cancer has shown that greater levels of leisure-time physical activity were associated with a lower risk of developing 13 different types of cancer. The risk of developing seven cancer types was 20%, or more, lower among the...
FDA Approves Lenvatinib in Combination With Everolimus in Advanced Renal Cell Carcinoma
On May 13, 2016, the U.S. Food and Drug Administration (FDA) approved lenvatinib capsules (Lenvima) in combination with everolimus (Afinitor) for the treatment of advanced renal cell carcinoma following one prior antiangiogenic therapy. Lenvatinib was first approved in 2015 for the treatment of...
Atezolizumab in Previously Treated Advanced Urothelial Carcinoma
The recent study by Rosenberg et al in The Lancet—summarized in this issue of The ASCO Post—is a very important paper in the field of bladder cancer therapy.1 It is the first phase II trial in metastatic transitional cell carcinoma that demonstrates the single-agent activity of the...
Suresh Senan, MRCP, FRCR, PhD, Receives 2016 Heine H. Hansen Award
The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) have announced the 2016 Heine H. Hansen (HHH) Award recipient: Suresh Senan, MRCP, FRCR, PhD. The award was presented at the European Lung Cancer Conference (ELCC) 2016, held on...
Al B. Benson III, MD, Elected President of the National Patient Advocate Foundation Executive Board
Al B. Benson III, MD, Associate Director for Cooperative Groups at the Lurie Cancer Center, has been elected President of the National Patient Advocate Foundation’s (NPAF) Executive Board. An oncologist and Professor of Medicine in the Division of Hematology/Oncology at the Feinberg School of...
Curb Your Enthusiasm: No Benefit of Adjuvant Sorafenib or Sunitinib in Nonmetastatic Renal Cell Carcinoma
Renal cell carcinoma is the most common cancer of the kidneys. Up to 30% of patients present with advanced/metastatic disease, and recurrence can develop in patients at high risk treated by nephrectomy for localized tumors. Renal cell carcinoma is notoriously resistant to chemotherapy and...
ASCO and European Association of Urology Agree on Bladder Cancer Guidelines
I like economies of scale, and thus it makes perfect sense that ASCO has set a formal process to allow potential endorsement of selected guidelines from other organizations, rather than redoing the whole process. Recently, we have seen the publication of a formal endorsement of the European...
ASCO Endorses European Association of Urology Guideline on Muscle-Invasive and Metastatic Bladder Cancers
As reported in the Journal of Clinical Oncology by Matthew I. Milowsky, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center, and colleagues,1 ASCO has endorsed the European Association of Urology clinical practice guideline on muscle-invasive and metastatic bladder...
A Quick Look at the Benefits of HPV Vaccination
In the United States, only 36% of girls and 14% of boys ages 11 to 13 are fully vaccinated against HPV. Last month, ASCO addressed this issue in a statement urging aggressive efforts to increase vaccination and prevent cancer. Your patients can quickly learn some facts about this underused form of...
Enhance Your Annual Meeting Experience With Attendee Resources
Next month, more than 30,000 oncology professionals will gather in Chicago for the 2016 ASCO Annual Meeting. This year’s theme, “Collective Wisdom: The Future of Patient-Centered Care and Research,” highlights the value of the combined knowledge of the global oncology community, spanning across...
Four Reasons to Use Social Media at the ASCO Annual Meeting
Join the discussion: Use #ASCO16 on Twitter to follow and participate in the conversation around the Annual Meeting in real time! During last year’s Annual Meeting, more than 12,400 individuals sent over 59,000 tweets, reaching an estimated 262 million people on Twitter. Tweets about the Meeting ...
ASCO Urges Aggressive Efforts to Increase HPV Vaccination and Prevent Cancer
On Monday, April 11, ASCO released a policy statement calling on member oncologists to help lead a push for all adolescents and young adults to be vaccinated against cervical and other cancer. Use of human papillomavirus (HPV) vaccines should be rapidly expanded to protect thousands of young...
ExteNET Trial of Neratinib: One Size Does Not Fit All in HER2-Positive Breast Cancer
Neratinib is an oral anti-HER2 tyrosine kinase inhibitor that has shown promising activity in the treatment of HER2-positive metastatic breast cancer.1 It differs from monoclonal antibodies such as trastuzumab (Herceptin) because, as a small molecule, neratinib blocks the ATP binding site on the...
Lifang Hou, MD, PhD, Named Director of Global Health at the Lurie Cancer Center
Lifang Hou, MD, PhD, has been appointed Director of Global Health for the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Dr. Hou brings her extensive experience in identifying risk factors and molecular biomarkers predictive of cancer risk and mortality, her interest in...
